Science News
from research organizations

Possible Risk Group For Statin Use

Date:
March 29, 2009
Source:
American Society for Biochemistry and Molecular Biology
Summary:
In a study of over 1,000 individuals with coronary artery disease, researchers have found that high levels of an enzyme called PLTP significantly increased the risk of heart attack in the subset of patients taking statins, suggesting that high levels of PLTP in the blood should be a consideration for potential statin treatment.
Share:
       
Total shares:  
FULL STORY

In a patient study of over 1,000 individuals with coronary artery disease (CAD), researchers have found that high levels of an enzyme called PLTP significantly increased the risk of heart attack in the subset of patients taking statins. While follow-up studies will be needed to tease out the exact connection between PLTP and statins, this connection does suggest levels of PLTP in the blood should be a consideration for potential statin treatment.

PLTP (phospholipid transferprotein) is involved in the metabolism of cholesterol-containing molecules like LDL and HDL, and therefore has been associated with atherosclerosis and heart disease. The exact role of PLTP in cardiovascular health remains debated, though, so Axel Schlitt and colleagues measured PLTP levels in 1,085 patients with CAD and then tracked how PLTP related to clinical outcome.

During the follow-up period (~5.1 years), 156 of the trial subjects suffered a fatal or non-fatal heart attack, including 47 individuals who were taking statins (out of 395 total statin patients). The researchers found that in this statin subset, PLTP levels were a significant predictor of cardiovascular outcome. In the total cohort, PLTP levels and outcome were not associated.

So while the statin patients experienced a lower overall rate of heart attack (12% vs. 15% -though the researchers note it's not especially significant, statistically), some individuals taking these drugs are at higher risk than normal. Schlitt and colleagues hypothesize that the high PLTP levels may blunt the beneficial effects of statins, though additional studies will certainly be needed.


Story Source:

The above story is based on materials provided by American Society for Biochemistry and Molecular Biology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Axel Schlitt, Stefan Blankenberg, Christoph Bickel, Karl J. Lackner, Gunnar H. Heine, Michael Buerke, Karl Werdan, Lars Maegdefessel, Uwe Raaz, Hans J. Rupprecht, Munzel T, Xian-Cheng Jiang. Phospholipid Transfer Protein Activity is a Risk Factor for subsequent Cardiovascular Events in Coronary Artery Disease Patients under Statin Therapy: the AtheroGene Study. Journal of Lipid Research, (in press)

Cite This Page:

American Society for Biochemistry and Molecular Biology. "Possible Risk Group For Statin Use." ScienceDaily. ScienceDaily, 29 March 2009. <www.sciencedaily.com/releases/2009/03/090323143904.htm>.
American Society for Biochemistry and Molecular Biology. (2009, March 29). Possible Risk Group For Statin Use. ScienceDaily. Retrieved May 22, 2015 from www.sciencedaily.com/releases/2009/03/090323143904.htm
American Society for Biochemistry and Molecular Biology. "Possible Risk Group For Statin Use." ScienceDaily. www.sciencedaily.com/releases/2009/03/090323143904.htm (accessed May 22, 2015).

Share This Page:


Health & Medicine News
May 22, 2015

Latest Headlines
updated 12:56 pm ET